ReviewCancers2019
Platelets as Key Factors in Hepatocellular Carcinoma.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 97 citations in OpenAlex.
- The role of platelets in the hepatocellular carcinoma immune microenvironment and their clinical prospects: a comprehensive review.Medical oncology (Northwood, London, England) · 2026Review
- Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach.Nature reviews. Gastroenterology & hepatology · 2026Review
- Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Article
- HALP Score in Predicting Post-Liver Transplant Outcomes in Patients with Hepatocellular Carcinoma.Journal of clinical medicine · 2026Article
- Risk Factors for Hepatocellular Carcinoma: Findings from a Case-Control Study in Vietnam.Research square · 2026Article
- Platelet-to-high-density lipoprotein ratio predicts postoperative overall survival in hepatocellular carcinoma: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Platelet-mediated progression of fatty liver disease in metabolic dysfunction-associated steatohepatitis: a pathophysiological review.Frontiers in medicine · 2026Review
- Development and Validation of a Nomogram Predictive Model for Massive Ascites After Hepatectomy in Patients with Primary Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Minimal clinical predictors enable machine learning detection of hepatocellular carcinoma in a Filipino cohort.Scientific reports · 2025Article
- Time of Day-Dependent Responses to Cisplatin Treatment in a Male Mouse Model of Hepatoma.Journal of biological rhythms · 2025Article
- The causal relationship between platelet indices and liver cancer: a bidirectional two-sample Mendelian randomization study.Discover oncology · 2025Article
- Combining serologic biomarkers with the PAGE B score improves risk stratification for hepatocellular carcinoma development among chronic hepatitis B patients.Scientific reports · 2025Article
- Association of non-insulin-based insulin resistance indices, mean platelet volume and prostate cancer: a cross-sectional study.BMC cancer · 2025Article
- Article
- Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response.The Journal of pathology · 2025Article
- Relationships Among Serological Indicators andCombinatorial chemistry & high throughput screening · 2025Article
- Predictive role of neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index for mortality in patients with MASLD.Scientific reports · 2024Article
- Association between antithrombotic agents use and hepatocellular carcinoma risk: a two-sample mendelian randomization analysis.Journal of cancer research and clinical oncology · 2024Article
- Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a primary liver cancer that usually develops in the setting of chronic inflammation and liver damage. The hepatic microenvironment plays a crucial role in the disease development, as players such as hepatic stellate cells, resident liver macrophages (Kupffer cells), endothelial cells, extracellular matrix, and a variety of immune cells interact in highly complex and intertwined signaling pathways. A key factor in these cross-talks are platelets, whose role in cancer has gained growing evidence in recent years. Platelets have been reported to promote HCC cell proliferation and invasion, but their involvement goes beyond the direct effect on tumor cells, as they are known to play a role in pro-fibrinogenic signaling and the hepatic immune response, as well as in mediating interactions between these factors in the stroma. Anti-platelet therapy has been shown to ameliorate liver injury and improve the disease outcome. However, platelets have also been shown to play a crucial role in liver regeneration after organ damage. Therefore, the timing and microenvironmental setting need to be kept in mind when assessing the potential effect and therapeutic value of platelets in the disease progression, while further studies are needed for understanding the role of platelets in patients with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.